Darotropium
As of the edition of 20 October 2026, Darotropium is a small molecule: went quiet in 2009; acts on CHRM1, CHRM2 and CHRM3 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2009
- Kind
- Small molecule
- Registered trials
- 11, 0 stopped early
- Disease areas
- Lungs and airways; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 3 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Darotropium.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product3 company-target rows are on route A because of Darotropium.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 5 | 5 | 0 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2005 to now |